Assenagon Asset Management S.A. Lowers Holdings in GeneDx Holdings Corp. $WGS

Assenagon Asset Management S.A. lowered its position in GeneDx Holdings Corp. (NASDAQ:WGS) by 53.8% during the 1st quarter, Holdings Channel reports. The firm owned 95,128 shares of the company’s stock after selling 110,767 shares during the quarter. Assenagon Asset Management S.A.’s holdings in GeneDx were worth $6,109,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of WGS. Kestra Advisory Services LLC bought a new stake in GeneDx during the 4th quarter valued at $27,000. Quarry LP lifted its holdings in shares of GeneDx by 248.8% in the 3rd quarter. Quarry LP now owns 293 shares of the company’s stock worth $32,000 after buying an additional 209 shares during the period. Ramirez Asset Management Inc. bought a new position in shares of GeneDx during the 4th quarter worth $33,000. Greenline Wealth Management LLC purchased a new position in shares of GeneDx during the fourth quarter valued at $33,000. Finally, Bank Julius Baer & Co. Ltd Zurich purchased a new position in shares of GeneDx during the fourth quarter valued at $35,000. 61.72% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In related news, CFO Kevin Feeley sold 3,729 shares of the business’s stock in a transaction that occurred on Tuesday, June 16th. The shares were sold at an average price of $60.77, for a total transaction of $226,611.33. Following the completion of the transaction, the chief financial officer owned 39,954 shares in the company, valued at $2,428,004.58. The trade was a 8.54% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Casdin Capital, Llc bought 50,000 shares of the firm’s stock in a transaction that occurred on Friday, June 5th. The shares were purchased at an average cost of $52.86 per share, with a total value of $2,643,000.00. Following the transaction, the director directly owned 3,707,164 shares of the company’s stock, valued at $195,960,689.04. The trade was a 1.37% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last ninety days, insiders acquired 2,256,420 shares of company stock valued at $93,144,340 and sold 21,699 shares valued at $1,295,646. 25.17% of the stock is currently owned by insiders.

Key GeneDx News

Here are the key news stories impacting GeneDx this week:

• Positive Sentiment: No clearly positive company-specific catalysts were included in the latest news flow.
• Neutral Sentiment: Multiple law firms, including Rosen, Robbins Geller, The Schall Law Firm, Pomerantz, and others, issued investor reminders and deadline notices related to the existing GeneDx securities class action, keeping the stock in the spotlight. Article: ROSEN, NATIONALLY REGARDED LAWYERS, Encourages GeneDx Holdings Corp. Investors to Secure Counsel Before Important Deadline in Securities Class Action – WGS
• Neutral Sentiment: Hagens Berman said it is investigating claims in the securities class action and highlighted allegations that GeneDx misled investors about the Fabric Genomics deal and synergy potential. Article: HBSS Investigates Claims Against GeneDx Holdings (WGS) in Securities Class Action Suit Following Massive Impairment Charge
• Neutral Sentiment: Short-interest data released this week showed unusual reporting, but the figures were listed as zero shares, offering little meaningful trading signal.
• Negative Sentiment: The repeated class action announcements and deadline reminders may weigh on sentiment by increasing legal overhang and reminding investors of the stock’s prior sharp selloff after the weak quarterly report.
• Negative Sentiment: The core allegations are that GeneDx’s disclosures around Fabric Genomics and related acquisition benefits were misleading, which could heighten concerns about management credibility and financial risk. Article: GeneDx Holdings Corp. (WGS) Investors: August 3, 2026, Deadline in Securities Fraud Class Action Lawsuit

GeneDx Stock Performance

WGS opened at $69.82 on Monday. The company has a current ratio of 3.09, a quick ratio of 2.95 and a debt-to-equity ratio of 0.38. The firm has a market cap of $2.07 billion, a price-to-earnings ratio of -26.05 and a beta of 1.96. GeneDx Holdings Corp. has a 12 month low of $32.21 and a 12 month high of $170.87. The stock has a fifty day moving average price of $54.26 and a 200-day moving average price of $82.52.

GeneDx (NASDAQ:WGS) last issued its quarterly earnings data on Monday, May 4th. The company reported ($0.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.22). GeneDx had a negative net margin of 17.58% and a positive return on equity of 9.15%. The company had revenue of $102.25 million for the quarter, compared to the consensus estimate of $112.46 million. During the same period in the previous year, the business earned ($0.23) EPS. As a group, equities research analysts anticipate that GeneDx Holdings Corp. will post -1 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several analysts recently weighed in on the company. Guggenheim decreased their price objective on GeneDx from $100.00 to $70.00 and set a “buy” rating for the company in a report on Tuesday, May 5th. BTIG Research cut their target price on shares of GeneDx from $170.00 to $90.00 and set a “buy” rating on the stock in a research report on Tuesday, May 5th. Wells Fargo & Company reissued an “overweight” rating and set a $75.00 target price (down from $155.00) on shares of GeneDx in a research report on Tuesday, May 5th. Zacks Research lowered shares of GeneDx from a “strong-buy” rating to a “hold” rating in a report on Friday, April 24th. Finally, Craig Hallum reaffirmed a “buy” rating and issued a $85.00 price target on shares of GeneDx in a research report on Tuesday, May 5th. Six equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, GeneDx currently has a consensus rating of “Moderate Buy” and a consensus target price of $86.86.

About GeneDx

GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.

Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.